1189 related articles for article (PubMed ID: 20673995)
1. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Greenway FL; Fujioka K; Plodkowski RA; Mudaliar S; Guttadauria M; Erickson J; Kim DD; Dunayevich E;
Lancet; 2010 Aug; 376(9741):595-605. PubMed ID: 20673995
[TBL] [Abstract][Full Text] [Related]
2. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.
Gadde KM; Allison DB; Ryan DH; Peterson CA; Troupin B; Schwiers ML; Day WW
Lancet; 2011 Apr; 377(9774):1341-52. PubMed ID: 21481449
[TBL] [Abstract][Full Text] [Related]
3. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II).
Apovian CM; Aronne L; Rubino D; Still C; Wyatt H; Burns C; Kim D; Dunayevich E;
Obesity (Silver Spring); 2013 May; 21(5):935-43. PubMed ID: 23408728
[TBL] [Abstract][Full Text] [Related]
4. Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial.
Nissen SE; Wolski KE; Prcela L; Wadden T; Buse JB; Bakris G; Perez A; Smith SR
JAMA; 2016 Mar; 315(10):990-1004. PubMed ID: 26954408
[TBL] [Abstract][Full Text] [Related]
5. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.
Wadden TA; Foreyt JP; Foster GD; Hill JO; Klein S; O'Neil PM; Perri MG; Pi-Sunyer FX; Rock CL; Erickson JS; Maier HN; Kim DD; Dunayevich E
Obesity (Silver Spring); 2011 Jan; 19(1):110-20. PubMed ID: 20559296
[TBL] [Abstract][Full Text] [Related]
6. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo.
Greenway FL; Dunayevich E; Tollefson G; Erickson J; Guttadauria M; Fujioka K; Cowley MA;
J Clin Endocrinol Metab; 2009 Dec; 94(12):4898-906. PubMed ID: 19846734
[TBL] [Abstract][Full Text] [Related]
7. Naltrexone ER/Bupropion ER: A Review in Obesity Management.
Greig SL; Keating GM
Drugs; 2015 Jul; 75(11):1269-80. PubMed ID: 26105116
[TBL] [Abstract][Full Text] [Related]
8. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial.
Astrup A; Madsbad S; Breum L; Jensen TJ; Kroustrup JP; Larsen TM
Lancet; 2008 Nov; 372(9653):1906-1913. PubMed ID: 18950853
[TBL] [Abstract][Full Text] [Related]
9. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes.
Hollander P; Gupta AK; Plodkowski R; Greenway F; Bays H; Burns C; Klassen P; Fujioka K;
Diabetes Care; 2013 Dec; 36(12):4022-9. PubMed ID: 24144653
[TBL] [Abstract][Full Text] [Related]
10. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.
Lau DCW; Erichsen L; Francisco AM; Satylganova A; le Roux CW; McGowan B; Pedersen SD; Pietiläinen KH; Rubino D; Batterham RL
Lancet; 2021 Dec; 398(10317):2160-2172. PubMed ID: 34798060
[TBL] [Abstract][Full Text] [Related]
11. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.
Kadowaki T; Isendahl J; Khalid U; Lee SY; Nishida T; Ogawa W; Tobe K; Yamauchi T; Lim S;
Lancet Diabetes Endocrinol; 2022 Mar; 10(3):193-206. PubMed ID: 35131037
[TBL] [Abstract][Full Text] [Related]
12. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study.
Astrup A; Rössner S; Van Gaal L; Rissanen A; Niskanen L; Al Hakim M; Madsen J; Rasmussen MF; Lean ME;
Lancet; 2009 Nov; 374(9701):1606-16. PubMed ID: 19853906
[TBL] [Abstract][Full Text] [Related]
13. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms.
Jain AK; Kaplan RA; Gadde KM; Wadden TA; Allison DB; Brewer ER; Leadbetter RA; Richard N; Haight B; Jamerson BD; Buaron KS; Metz A
Obes Res; 2002 Oct; 10(10):1049-56. PubMed ID: 12376586
[TBL] [Abstract][Full Text] [Related]
14. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women.
Gadde KM; Parker CB; Maner LG; Wagner HR; Logue EJ; Drezner MK; Krishnan KR
Obes Res; 2001 Sep; 9(9):544-51. PubMed ID: 11557835
[TBL] [Abstract][Full Text] [Related]
15. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects.
Wilding J; Van Gaal L; Rissanen A; Vercruysse F; Fitchet M;
Int J Obes Relat Metab Disord; 2004 Nov; 28(11):1399-410. PubMed ID: 15486569
[TBL] [Abstract][Full Text] [Related]
16. Naltrexone + bupropion (Mysimba). Too risky for only modest weight loss.
Prescrire Int; 2015 Oct; 24(164):229-33. PubMed ID: 26594724
[TBL] [Abstract][Full Text] [Related]
17. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
[TBL] [Abstract][Full Text] [Related]
18. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial.
Knop FK; Aroda VR; do Vale RD; Holst-Hansen T; Laursen PN; Rosenstock J; Rubino DM; Garvey WT;
Lancet; 2023 Aug; 402(10403):705-719. PubMed ID: 37385278
[TBL] [Abstract][Full Text] [Related]
19. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.
Enebo LB; Berthelsen KK; Kankam M; Lund MT; Rubino DM; Satylganova A; Lau DCW
Lancet; 2021 May; 397(10286):1736-1748. PubMed ID: 33894838
[TBL] [Abstract][Full Text] [Related]
20. Zonisamide for weight loss in obese adults: a randomized controlled trial.
Gadde KM; Franciscy DM; Wagner HR; Krishnan KR
JAMA; 2003 Apr; 289(14):1820-5. PubMed ID: 12684361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
